A Convergence of Chemistry And Biology To Create Better Medicine

WHAT WE BELIEVE

Ambrx is developing innovative protein therapeutics that preserve potency, reduce dosing frequency and improve homogeneity of the drug substance.

Learn More

Our Technology

Ambrx is harnessing the power of an expanded genetic code to optimize the performance of therapeutic proteins, peptides, bi-specifics and full length antibody conjugates

Learn More

PIPELINE

Ambrx has a number of highly differentiated product candidates at various stages of development in its pipeline, with a focus on “best in class” biopharmaceutical product opportunities.

Learn More

Partnerships

Partnerships for Next Generation Biologics

Learn More

News

Apr 29, 2014

SAN DIEGO and TAIZHOU CITY, China, April 29, 2014 – Ambrx Inc. and Zhejiang Hisun Pharmaceutical Company Ltd. (SSE Code:...

A Convergence of Chemistry And Biology To Create Better Medicine

WHAT WE BELIEVE

Our Technology

PIPELINE

Partnerships

News

Ambrx and Zhejiang Hisun Pharmaceutical to Collaborate on the Development and Commercialization of Bispecifics for Cancer

Ambrx and Zhejiang Medicine Co. Ltd. Form Collaboration to Develop and Commercialize Ambrx’s Antibody Drug Conjugate for Breast Cancer

Ambrx Appoints Lawson Macartney, Ph.D., DVM, Chief Executive Officer